Slow progression.

The genomic make-up of prostate cancer as it learns to evade common therapies. This analysis demonstrates an enrichment of TP53, RB1, AR and PI3K gene defects in castrate-resistant mets as compared to initial treatment-naive prostate biopsies from the same patients. | Mateo, J Clin Invest 2019


Popular Posts